<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03369106</url>
  </required_header>
  <id_info>
    <org_study_id>C16-114</org_study_id>
    <secondary_id>2017-A01844-49</secondary_id>
    <nct_id>NCT03369106</nct_id>
  </id_info>
  <brief_title>Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study</brief_title>
  <acronym>SEP-BIO-PROG</acronym>
  <official_title>Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will identify a combination of disease severity markers (genetic, immunology,
      epigenetic, imaging) associated with disease severity and progression in a cohort of patients
      with multiple sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The heterogeneity of multiple sclerosis evolution relies on several pathophysiological
      mechanisms including neuroinflammation, neurodegeneration and remyelination and repair
      mechanisms.

      The study will identify markers of disease severity in a longitudinal cohort of patients with
      multiple sclerosis who are siblings (both siblings having multiple sclerosis) including:
      biological markers (genetic, immunological and epigenetic markers, advanced MRI markers). An
      integrative model to predict disease progression will be proposed based on multimodal
      markers.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2017</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Expanded disability status scale</measure>
    <time_frame>Baseline and 18 months</time_frame>
    <description>Change in the neurological assessment of disability related to multiple sclerosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in neuropsychological scores</measure>
    <time_frame>Baseline and 18 months</time_frame>
    <description>Change in the battery of neuropsychological tests adapted for multiple sclerosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in T2 lesion volume</measure>
    <time_frame>Baseline and 18 months</time_frame>
    <description>Change in volume of T2 lesion in the white matter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey matter volume change</measure>
    <time_frame>Baseline and 18 months</time_frame>
    <description>Change in cerebral grey matter volume</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Multiple Sclerosis siblings</arm_group_label>
    <description>Group of siblings having multiple sclerosis, n=120 Composite severity score calculation for all subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Composite severity score calculation</intervention_name>
    <description>Neurological examination, cognitive testing, and MRI exam</description>
    <arm_group_label>Multiple Sclerosis siblings</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Multiple Sclerosis siblings Group of siblings having multiple sclerosis, n=120
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically isolated syndrome or Multiple sclerosis (2010 Mc Donald criteria)

          -  Sibling having Clinically isolated syndrome or Multiple sclerosis (2010 Mc Donald
             criteria) willing to participate to the study

          -  Affiliated to the French social security or equivalent

        Exclusion Criteria:

          -  Cyclophosphamide, mitoxantrone or methylprednisolone infusion within one month before
             inclusion

          -  Multiple sclerosis relapse within one month before inclusion

          -  Concomittant severe or uncontrolled disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Céline Louapre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut du Cerveau et de la Moelle Epinière</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Céline Louapre, MD, PhD</last_name>
    <phone>+33 1 42 16 57 66</phone>
    <email>celine.louapre@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CIC Neurosciences Institut du Cerveau et de la Moelle Epinière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Céline Louapre, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

